Renal cell carcinoma guideline;Guía del carcinoma de células renales

Actas Urologicas Espanolas

Volumn 33, Issue 3, 2009, Pages 270-279

  Ljungberg, Börje ^a   Hanbury, Damián C ^b   Kuczyk, Marcus A ^c   Merseburger, Axel S ^c   Mulders, Peter F A ^d   Patard, Jean Jacques ^e   Sinescu, Ioanel C ^f   Fadrique, Gonzalo García ^g  

^a UMEÅ UNIVERSITY   (Sweden)

^b Hospital de Lister   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f Instituto Clínico Fundeni   (Romania)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Diagnosis; Follow up; Guidelines; Recommendations; Renal cell carcinoma; Treatment

Indexed keywords

EID: 67650736075     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(09)74140-3     Document Type: Review

References (64)

1. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001). Lyon, France, 2001.
2. Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg. 2004;93(2):88-96.
3. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E, Zbar B. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131-133.
4. Pischon T, Lahmann PH, Boeing H, Tjonneland A, Halkjaer J, Overvad K, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006; 118(3):728-738.
5. Patard JJ, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Prognostic significance of the mode of detection in renal tumours. BJU Int. 2002;90(4):358-363.
6. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172(3):863-866.
7. Novick AC, Campbell SC. Renal tumours. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology. Philadelphia: WB Saunders; 2002. p. 2672-731.]
8. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7(4): 135-40.
9. Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol. 2003;44(2):226-232.
10. Sufrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol. 1989;7(3): 158-171.
11. Heidenreich A, Ravery V; European Society of Oncological Urology. Preoperative imaging in renal cell cancer. World J Urol. 2004;22(5):307-315.
12. Hricak H, Demas BE, Williams RD, McNamara MT, Hedgcock MW, Amparo EG, et al. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology. 1985;154(3):709-715.
13. Gupta NP, Ansari MS, Khaitan A, Sivaramakrishna MS, Hemal AK, Dogra PN, et al. Impact of imaging and thrombus level in management of renal cell carcinoma extending to veins. Urol Int. 2004;72(2):129-134.
14. Sobin LH. The WHO histological classification of urinary bladder tumours. Urol Res. 1978;6(4): 193-195.
15. Ficarra V, Schips L, Guillè F, Li G, De La Taille A, Prayer Galetti T, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005 Sep l;104(5):968-974.
16. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol. 2005;174(4 Pt 1):1218-1221.
17. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003; 169 (3):899-903.
18. Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49(2):324-331.
19. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004. p7.
20. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32(6):590-595.
21. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006;3(1): e13.
22. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. 1969. J Urol. 2002:167(2 Pt 2):873-875.
23. Kuczyk M, Münch T, Machtens S, Bokemeyer C, Wefer A, Hartmann J, et al. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int. 2002;89(6):517-522.
24. Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol. 2005:48(2) :252-257 .
25. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol. 1996;155(2):448-450.
26. Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int. 2003:92(3) :240-244 .
27. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999; 162(6): 1930-1933.
28. McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology. 2002;60(6): 1003-1009.
29. Link RE, Bhayani SB, Allaf ME, Varkarakis I, Inagaki T, Rogers C, et al. Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. J Urol. 2005;173(5): 1690-1694
30. Novick AC. Laparoscopic and partial nephrectomy. Clin Cancer Res. 2004; 10(18 Pt 2):6322S-6327S.
31. Becker F, Siemer S, Humke U, Hack M, Ziegler M, Stockle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients. Eur Urol. 2006;49(2):308-313.
32. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already?. Curr Opin Urol. 2005;15(2):75-78.
33. Matin SF, Gill IS, Worley S, Novick AC. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm. or less renal tumor with a normal contralateral kidney. J Urol. 2002; 168(4 Pt 1): 1356-1359.
34. Lewin JS, Nour SG, Connell CF, Sulman A, Duerk JL, Resnick MI, et al. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology. 2004;232(3):835-845.
35. Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, et al. Renal cryoablation: outcome at 3 years. J Urol. 2005;173(6):1903-1907.
36. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363(9409):594-599.
37. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171 (3): 1071-1076.
38. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol. 2000;34(4):246-251.
39. Van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: A mul-ticenter retrospective analysis. Eur Urol. 1999:35(3): 197-203.
40. Fossá SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol. 1982;8(6):340-342.
41. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004:363(9422): 1665-1672.
42. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261-266.
43. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003:170(4 Pt 1):1141-1145.
44. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet, 1999(353):14-17.
45. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al: Prospective randomized trial of high-dose inter-leukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85(8):622-632.
46. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleu-kin-2 therapy. J Clin Oncol. 1995 Mar; 13(3):688-696.
47. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 ;23(1): 133-141.
48. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127-3132.
49. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998 Apr 30;338(18): 1272-1278.
50. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23 (18):4172-4178.
51. Atzpodien J, Kirchner H, IlligerHJ, MetznerB, UkenaD, Schott H, Funke PJ, Gramatzki M, Jürgenson S, Wandert T, Patzelt T, Reitz M.: IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer. 2001 Oct 19;85(8): 1130-1136.
52. Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the Importance of smart drugs in renal cell carcinoma. Eur Urol. 2006 Apr;49(4):633-643.
53. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12(24):7215-7120.
54. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007:356(2): 125-134.
55. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 7;295(21):2516-2524.
56. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1): 16-24.
57. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-124.
58. Hudes G, Carducci M, Tomczak P, et al. A phase 3 randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol (Meeting Abstracts) 2006;24:LBA4.
59. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005; 173(6): 1853-1862.
60. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Flcarra V. Safety and efficacy of partial nephrectomy for all Tl tumors based on an international multicenter experience. J Urol,. 2004;171(6 Pt l):2181-2435.
61. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84(4):405-411.
62. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(l):63-67.
63. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174(2): 466-472.
64. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer2003;97(7): 1663-1671.